Alkermes' alixorexton has become the first drug in the orexin 2 receptor agonist class to show efficacy in phase 2 trials involving patients with both main subtypes of sleep disorder narcolepsy.

We conducted a phase 2, randomized, placebo-controlled trial of TAK-994, an oral orexin receptor 2–selective agonist, in patients with narcolepsy type 1. Patients with confirmed narcolepsy type 1 ...

That overwhelming sleepiness dragging you down might not just be from staying up too late scrolling through TikTok. While everyone occasionally battles the afternoon slump, people with hypersomnia or ...

Amid the coronavirus disease 2019 pandemic, patients with narcolepsy reported changes in bedtime and waking schedules, as well as an increase in adverse symptoms such as cataplexy and sleep paralysis.

A new study has demonstrated a new way to treat narcolepsy-related nightmares. The scientists combined cognitive behavioral therapy (CBT) and lucid dreaming to help patients in a small clinical trial.

Nightmares affect 30-40% of patients with narcolepsy, but are often overlooked Treatment can transform patients’ sleep and their daytime mood in a matter of weeks Study found overall reduction in ...